IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies

Journal of Investigative Dermatology

Volumn 135, Issue 8, 2015, Pages 1946-1953

  Blauvelt, Andrew ^a   Lebwohl, Mark G ^b   Bissonnette, Robert ^c  

^a OREGON MEDICAL RESEARCH CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INNOVADERM RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HYPERIMMUNE GLOBULIN; INTERLEUKIN 17; INTERLEUKIN 23; BIOLOGICAL PRODUCT;

ANTIBODY PRODUCTION; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENE MUTATION; HELPER CELL; HUMAN; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SALMONELLOSIS; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG EFFECTS; GENETICS; IMMUNE SYSTEM DISEASES; MUTATION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PATHOPHYSIOLOGY; PHYSIOLOGY; SALMONELLA INFECTIONS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BIOLOGICAL PRODUCTS; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-17; INTERLEUKIN-23; MUTATION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PHENOTYPE; PSORIASIS; SALMONELLA INFECTIONS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84937642086     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.144     Document Type: Review

References (71)

1. Akahoshi M, Nakashima H, Miyake K et al. (2003) Influence of interleukin-12 receptor β1 polymorphisms on tuberculosis. Hum Genet 112:237-43
2. Al-Muhsen S, Casanova JL (2008) The genetic heterogeneity of Mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 122: 1043-503
3. Altare F, Durandy A, Lammas D et al. (1998) Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280: 1432-5
4. Aujla SJ, Chan YR, Zheng M et al. (2008) IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14:275-81
5. Bedoya SK, Lam B, Lau K et al. (2013) Th17 cells in immunity and autoimmunity. Clin Dev Immunol 2013:986789
6. Blauvelt A (2008) T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 128:1064-7
7. Boisson-Dupuis S, Kong XF, Okada S et al. (2012) Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol 24:364-78
8. Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-85
9. Bustamante J, Boisson-Dupuis S, Jouanguy E et al. (2008) Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol 20:39-48
10. Cárdenes M, Angel-Moreno A, Fieschi C et al. (2010) Oesophageal squamous cell carcinoma in a young adult with IL-12Rβ1 deficiency. J Med Genet 47: 635-7
11. Chu WM (2013) Tumor necrosis factor. Cancer Lett 328:222-5
12. Cypowyj S, Picard C, Maródi L et al. (2012) Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol 42:2246-54
13. de Beaucoudrey L, Samarina A, Bustamante J et al. (2010) Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89:381-402
14. De Luca A, Zelante T, D'Angelo C et al. (2010) IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 3:361-73
15. Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339-50
16. Drewniak A, Gazendam RP, Tool AT et al. (2013) Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 121: 2385-92
17. Ferwerda B, Ferwerda G, Plantinga TS et al. (2009) Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 361:1760-7
18. Fieschi C, Bosticardo M, de Beaucoudrey L et al. (2004) A novel form of complete IL-12/IL-23 receptor β1 deficiency with cell surface-expressed nonfunctional receptors. Blood 104:2095-101
19. Fieschi C, Casanova JL (2003) The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol 33:1461-4
20. Fieschi C, Dupuis S, Catherinot E et al. (2003) Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor β1 deficiency: medical and immunological implications. J Exp Med 197:527-35
21. Focosi D, Maggi F, Pistello M et al. (2011) Immunosuppressive monoclonal antibodies: current and next generation. Clin Microbiol Infect 17: 1759-68
22. Furst DE (2010) The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 39:327-46
23. Gaffen SL (2011) Recent advances in the IL-17 cytokine family. Curr Opin Immunol 23:613-9
24. Girolomoni G, Mrowietz U, Paul C (2012) Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167:717-24
25. Godinez I, Keestra AM, Spees A et al. (2011) The IL-23 axis in Salmonella gastroenteritis. Cell Microbiol 13:1639-47
26. Hanna S, Etzioni A (2011) New host defense mechanisms against Candida species clarify the basis of clinical phenotypes. J Allergy Clin Immunol 127: 1433-7
27. Harper EG, Guo C, Rizzo H et al. (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129:2175-83
28. Hueber W, Patel DD, Dryja T et al. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72
29. Huppler AR, Bishu S, Gaffen SL (2012) Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther 14:217
30. Kagami S, Rizzo HL, Lee JJ et al. (2010) Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130:1373-83
31. Kellner H (2013) Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis 5: 141-52
32. Khader SA, Pearl JE, Sakamoto K et al. (2005) IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-? responses if IL-12p70 is available. J Immunol 175:788-95
33. Kim SY, Solomon DH (2010) Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 6:165-74
34. Kisand K, Bøe Wolff AS, Podkrajek KT et al. (2010) Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207:299-308
35. Kisand K, Lilic D, Casanova JL et al. (2011) Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 41:1517-27
36. Kluger N, Ranki A, Krohn K (2012) APECED: is this a model for failure of T cell and B cell tolerance? Front Immunol 3:232
37. Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68: 1136-45
38. Lilic D (2012) Unravelling fungal immunity through primary immune deficiencies. Curr Opin Microbiol 15:420-6
39. Liu L, Okada S, Kong XF et al. (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208:1635-48
40. Lynde CW, Poulin Y, Vender R et al. (2014) Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 71: 141-50
41. Ma CS, Chew GY, Simpson N et al. (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205:1551-7
42. MacLennan C, Fieschi C, Lammas DA et al. (2004) Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis 190:1755-7
43. Michalak-Stoma A, Pietrzak A, Szepietowski JC et al. (2011) Cytokine network in psoriasis revisited. Eur Cytokine Netw 22:160-8
44. Minegishi Y, Karasuyama H (2009) Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Int Immunol 21:105-12
45. Nwe SM, Champlain AH, Gordon KB (2013) Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol 9:677-82
46. O'Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol 2:37-45
47. + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 86:435-43
48. Ouederni M, Sanal O, Ikinciogullari A et al. (2014) Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. Clin Infect Dis 58:204-13
49. Patel DD, Lee DM, Kolbinger F et al. (2013) Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 72(Suppl 2): ii116-23
50. Puel A, Cypowyj S, Bustamante J et al. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65-8
51. Puel A, Cypowyj S, Maródi L et al. (2012) Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 12:616-22
52. Puel A, Döffinger R, Natividad A et al. (2010a) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207:291-7
53. Puel A, Picard C, Cypowyj S et al. (2010b) Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr Opin Immunol 22:467-74
54. Qu N, Xu M, Mizoguchi I et al. (2013) Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol 2013:968549
55. Raffatellu M, Santos RL, Verhoeven DE et al. (2008) Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 14:421-8
56. Ramirez-Alejo N, Blancas-Galicia L, Yamazaki-Nakashimada M et al. (2014) Molecular analysis for patients with IL-12 receptor β1 deficiency. Clin Genet 86:161-6
57. Res PC, Piskin G, de Boer OJ et al. (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5:e14108
58. Rizzo HL, Kagami S, Phillips KG et al. (2011) IL-23-mediated psoriasislike epidermal hyperplasia is dependent on IL-17A. J Immunol 186: 1495-502
59. Schimke LF, Sawalle-Belohradsky J, Roesler J et al. (2010) Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol 126:611-7.e1
60. Sillevis Smitt JH, Kuijpers TW (2013) Cutaneous manifestations of primary immunodeficiency. Curr Opin Pediatr 25:492-7
61. Szczawinska-Poplonyk A, Kycler Z, Pietrucha B et al. (2011) The hyperimmu-noglobulin E syndrome-clinical manifestation diversity in primary immune deficiency. Orphanet J Rare Dis 6:76
62. h 17 cell responses to Mycobacterium tuberculosis. Int Immunol 23:89-96
63. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunor-egulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-76
64. van de Veerdonk FL, Marijnissen RJ, Joosten LA et al. (2010) Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clin Exp Immunol 159:57-64
65. van de Veerdonk FL, Plantinga TS, Hoischen A et al. (2011) STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365:54-61
66. van de Vosse E, Haverkamp MH, Ramirez-Alejo N et al. (2013) IL-12Rβ1 deficiency: mutation update and description of the IL12RB1 variation database. Hum Mutat 34:1329-39
67. van den Berg WB, McInnes IB (2013) Th17 cells and IL-17A-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 43: 158-70
68. Waite JC, Skokos D (2012) Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012:819467
69. H17 cell deficiencies. J Allergy Clin Immunol 133:905-8 e3
70. Yilmaz SB, Cicek N, Coskun M et al. (2012) Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res 304: 465-9
71. Zelante T, De Luca A, D'Angelo C et al. (2009) IL-17/Th17 in anti-fungal immunity: what's new? Eur J Immunol 39:645-8